Humatrope (Somatropin)

Humatrope is indicated for several conditions associated with insufficient endogenous growth hormone production.

• Growth hormone deficiency in children, to promote linear growth and increase height velocity.
• Growth hormone deficiency in adults, to improve body composition, increase lean muscle mass, and enhance metabolic function.
• Turner syndrome, to increase stature when therapy is started early in childhood and continued through puberty.
• Chronic renal insufficiency in pediatric patients, to support growth and improve height outcomes despite reduced kidney function.
• Prader‑Willi syndrome, as part of a multidisciplinary approach to improve growth, body composition, and quality of life.

• Humatrope contains recombinant somatropin, which mimics endogenous human growth hormone. After subcutaneous injection, somatropin binds to growth‑hormone receptors on target cells, activating the JAK2‑STAT5 signaling pathway. This stimulates hepatic production of insulin‑like growth factor‑1 (IGF‑1) and promotes downstream anabolic effects, including protein synthesis, cartilage growth, and lipolysis, thereby supporting linear growth and metabolic regulation. It also contributes to bone mineralization and helps maintain glucose homeostasis.

Adverse reactions to Humatrope are reported across a range of frequencies and severities.

Common

• Injection site reactions such as pain, redness, swelling, or bruising that usually resolve within a few days.
• Headache of mild to moderate intensity, often transient and not requiring specific treatment.
• Transient joint or muscle aches, particularly in the limbs, that improve with continued therapy.
• Fluid retention causing mild peripheral edema, especially in the ankles or hands.

Serious

• Intracranial hypertension, which may present with headache, visual disturbances, papilledema, and requires immediate medical evaluation.
• Development of neutralizing antibodies that can diminish the therapeutic effect of somatropin and may necessitate discontinuation.
• Hyperglycemia or new‑onset diabetes mellitus, particularly in patients with pre‑existing risk factors, requiring glucose monitoring.

Before initiating Humatrope, clinicians should evaluate several safety considerations to minimize risks.

• Assess for active malignancies, as growth hormone may stimulate tumor growth.
• Review history of intracranial hypertension or unexplained visual symptoms.
• Evaluate glucose tolerance, especially in patients with diabetes risk factors.
• Monitor for signs of slipped epiphysis in growing children.
• Consider potential for fluid retention in patients with cardiac or renal impairment.
• Screen for hypersensitivity to any component of the formulation.
• Ensure proper storage and handling of the injectable solution to maintain potency.

Humatrope may interact with other medicines or substances that affect its efficacy or safety.

Avoid

• Concomitant use with glucocorticoids at high doses, which can blunt growth‑hormone effects.
• Co‑administration with insulin‑like growth factor‑1 (IGF‑1) therapy, as it may increase risk of hypoglycemia.
• High‑dose vitamin D supplementation, which may increase calcium absorption and risk of hypercalcemia.

Use with caution

• Antidiabetic agents, because Humatrope can raise blood glucose levels.
• Thyroid hormone replacement, since growth hormone may alter thyroid hormone metabolism.
• Oral estrogen therapy, which can reduce the pharmacodynamic response to somatropin.
• Corticosteroid inhalers, as systemic absorption may modestly interfere with growth‑hormone action.